Atmanirbhar Bharat and biotech manufacturing

Introduction

Atmanirbhar Bharat, or Self-Reliant India, is a national initiative aimed at strengthening India's domestic manufacturing capabilities, reducing excessive dependence on imports and promoting technological innovation across strategic industries. Biotechnology is an important component of this initiative because it contributes to healthcare, pharmaceuticals, agriculture, industrial production, environmental protection and scientific research.

Biotechnology manufacturing includes the production of vaccines, biological medicines, biosimilars, diagnostic kits, enzymes, biofertilisers, biopesticides, genetically engineered products and other biological materials. India has developed a significant biotechnology industry, particularly in vaccine manufacturing, generic medicines and biopharmaceutical production.

The Atmanirbhar Bharat initiative seeks to strengthen domestic research and development, encourage private investment, improve manufacturing infrastructure, promote technology transfer and develop indigenous biotechnology capabilities.

However, the expansion of biotechnology manufacturing also raises legal questions concerning intellectual property rights, biosafety, environmental protection, pharmaceutical regulation, foreign investment, technology licensing and quality control. Therefore, an effective legal framework is necessary to balance industrial development with public health, environmental safety and national economic interests.

Meaning and objectives of Atmanirbhar Bharat in biotechnology

Atmanirbhar Bharat promotes domestic production, innovation and technological independence. In biotechnology, the initiative focuses on developing indigenous capabilities throughout the manufacturing and research value chain.

Its major objectives include:

Domestic manufacturing: Increasing Indian production of vaccines, medicines, biological products and diagnostic technologies.

Research and development: Encouraging investment in biotechnology research and innovation.

Import substitution: Reducing dependence on imported biological materials, specialised equipment and pharmaceutical ingredients.

Technology transfer: Promoting collaboration between universities, research institutions and biotechnology companies.

Employment generation: Creating skilled employment opportunities in pharmaceutical and biotechnology industries.

Global competitiveness: Strengthening India's position as an international biotechnology manufacturing and export centre.

The initiative also supports the development of biotechnology start-ups, research parks, manufacturing clusters and specialised scientific infrastructure.

Government policies supporting biotech manufacturing

1. Production Linked Incentive Scheme

The Production Linked Incentive (PLI) schemes were introduced to strengthen domestic manufacturing in selected sectors.

The pharmaceutical PLI scheme supports domestic manufacturing of identified pharmaceutical products, including certain critical bulk drugs, drug intermediates and key starting materials.

The scheme is relevant to biotechnology because pharmaceutical manufacturing and biopharmaceutical supply chains depend on reliable access to essential materials and specialised production facilities.

Its broader objectives include improving domestic production capacity, encouraging investment and strengthening India's pharmaceutical supply chain.

2. National Biotechnology Development Strategy

The Department of Biotechnology (DBT) promotes biotechnology research, innovation and industrial development through national programmes and institutional support.

Its activities include:

Supporting biotechnology research institutions.

Encouraging public-private research partnerships.

Promoting biotechnology entrepreneurship.

Developing specialised research infrastructure.

Supporting indigenous biotechnology products.

Encouraging technology commercialisation.

These initiatives contribute to the development of a stronger domestic biotechnology manufacturing ecosystem.

3. Biotechnology Industry Research Assistance Council (BIRAC)

BIRAC was established by the Department of Biotechnology to promote innovation and entrepreneurship in biotechnology.

It supports start-ups, small enterprises and research institutions through funding programmes, incubation facilities and technology development assistance.

BIRAC helps bridge the gap between laboratory research and commercial manufacturing.

Its activities are particularly important for developing indigenous vaccines, diagnostics, medical devices and biological products.

4. National Biopharma Mission

The National Biopharma Mission, also known as Innovate in India for Inclusiveness, aims to strengthen India's biopharmaceutical innovation ecosystem.

It supports the development of vaccines, biosimilars, medical devices and other biotechnology products.

The mission promotes collaboration between industry, academic institutions and research organisations to accelerate the development and commercialisation of biotechnology innovations.

Legal framework governing biotechnology manufacturing in India

1. Patents Act, 1970

The Patents Act provides the principal legal framework for protecting qualifying biotechnology inventions in India.

It allows patent protection for inventions satisfying the requirements of novelty, inventive step and industrial applicability, subject to statutory exclusions.

Important provisions include:

Section 3(c): Excludes the discovery of living things or non-living substances occurring in nature.

Section 3(d): Restricts patent protection for certain new forms of known substances unless the statutory requirements are satisfied.

Section 3(j): Excludes plants and animals in whole or any part thereof, other than microorganisms, from patentability.

Section 48: Defines the rights of a patent holder.

These provisions influence investment decisions, technology licensing and commercialisation in biotechnology manufacturing.

2. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act regulates the import, manufacture, distribution and sale of drugs in India.

Biological medicines, vaccines and other regulated pharmaceutical products must comply with applicable licensing, quality and safety requirements.

The Central Drugs Standard Control Organisation (CDSCO) plays an important role in regulating pharmaceutical products and ensuring compliance with applicable standards.

3. New Drugs and Clinical Trials Rules, 2019

These Rules establish regulatory requirements concerning new drugs and clinical trials.

They are relevant to biotechnology manufacturing where products involve new biological medicines, vaccines or other regulated therapeutic technologies.

The framework addresses clinical trial permissions, ethics review, safety monitoring and regulatory approval.

4. Environment (Protection) Act, 1986

Biotechnology manufacturing may involve genetically engineered microorganisms, biological waste and potentially hazardous industrial processes.

The Environment (Protection) Act provides the legal basis for environmental protection and pollution control.

The Rules of 1989 further regulate specified activities involving hazardous microorganisms and genetically engineered organisms or cells.

5. Biological Diversity Act, 2002

The Biological Diversity Act, as amended in 2023, establishes rules concerning access to biological resources and associated benefit-sharing obligations.

Biotechnology companies using Indian biological resources may need to comply with applicable statutory requirements.

The framework seeks to promote conservation, sustainable utilisation and equitable sharing of benefits arising from biological resources.

6. Foreign Exchange Management Act, 1999

Foreign investment in biotechnology manufacturing is also governed by the Foreign Exchange Management Act and applicable foreign direct investment policy.

The FDI framework permits substantial foreign participation in many pharmaceutical and biotechnology activities, subject to the applicable sectoral conditions and government approval requirements.

Major legal challenges in biotech manufacturing

1. Intellectual property protection and technology transfer

Biotechnology manufacturing frequently depends on specialised technologies, patented biological processes and proprietary research.

Domestic manufacturers may face difficulties obtaining access to essential technologies because of licensing restrictions and high development costs.

The legal challenge is to balance patent protection with affordable technology transfer and domestic innovation.

2. Dependence on imported raw materials

India's biotechnology industry may depend on imported specialised chemicals, active pharmaceutical ingredients, laboratory equipment and manufacturing technologies.

Disruptions in international supply chains can affect domestic production.

Atmanirbhar Bharat therefore encourages indigenous manufacturing capabilities and reliable supply chains.

3. Biosafety and environmental compliance

Biotechnology manufacturing may involve genetically modified organisms and hazardous biological materials.

Manufacturers must follow applicable biosafety requirements, environmental standards and waste-management regulations.

Non-compliance may result in regulatory penalties, suspension of activities or other legal consequences.

4. Quality control and international standards

Indian biotechnology manufacturers must maintain appropriate manufacturing standards to ensure product quality, safety and effectiveness.

Compliance with applicable Good Manufacturing Practices (GMP), pharmaceutical regulations and international quality requirements is important for domestic and export markets.

5. Affordable access to biotechnology products

The commercialisation of advanced biological medicines and vaccines raises questions concerning pricing, availability and public health.

The legal framework must balance commercial incentives with the objective of ensuring affordable access to essential healthcare products.

6. Foreign investment and national interests

Foreign investment can bring advanced technology, capital and manufacturing expertise.

However, regulatory oversight remains important to protect strategic manufacturing capabilities, public health interests and compliance with Indian laws.

Important case laws and judicial principles

1. Novartis AG v. Union of India (2013)

The Supreme Court examined the patentability of a modified form of an existing pharmaceutical substance under Section 3(d) of the Patents Act, 1970.

The Court rejected the patent application because the claimed invention did not satisfy the enhanced efficacy requirement applicable under Section 3(d).

Legal principle: Patent protection must satisfy statutory requirements, and pharmaceutical innovation cannot automatically receive protection merely because an existing substance has been modified.

Relevance: The judgment is important for India's biotechnology manufacturing sector because it influences pharmaceutical patent protection, domestic manufacturing and access to affordable medicines.

2. Bayer Corporation v. Union of India (2014)

The case concerned the grant of compulsory licensing for the cancer medicine Nexavar under Section 84 of the Patents Act.

The legal dispute involved the relationship between patent rights, affordability, reasonable requirements of the public and availability of patented medicines in India.

Legal principle: Indian patent law permits compulsory licensing where statutory conditions are satisfied.

Relevance: The decision is significant for biotechnology manufacturers because it demonstrates how public health interests may be balanced against exclusive patent rights.

3. Dimminaco A.G. v. Controller of Patents and Designs (2002)

The Calcutta High Court examined the patentability of a manufacturing process involving a vaccine containing living organisms.

The Court rejected the argument that a process could not be patented merely because its final product contained living microorganisms.

Legal principle: Processes involving living microorganisms are not automatically excluded from patent protection.

Relevance: This judgment is important for indigenous vaccine manufacturing and biotechnology process innovation in India.

4. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

The Supreme Court considered patent disputes concerning genetically modified cotton technology and the relationship between patent protection and plant variety legislation.

The judgment examined the legal treatment of biotechnology-related inventions under Indian intellectual property law.

Legal principle: Biotechnology inventions must be assessed under the applicable patentability provisions and statutory exclusions.

Relevance: The decision provides guidance for companies investing in agricultural biotechnology, genetic technologies and commercial research.

5. Vellore Citizens' Welfare Forum v. Union of India (1996)

The Supreme Court recognised the precautionary principle and polluter pays principle as essential components of Indian environmental law.

Legal principle: Industrial development must operate consistently with environmental protection and the prevention of ecological damage.

Relevance: Biotechnology manufacturing facilities must adopt appropriate environmental safeguards, particularly where production involves hazardous biological materials or industrial waste.

Role of biotechnology manufacturing in India's economic development

Atmanirbhar Bharat can strengthen India's biotechnology sector through domestic manufacturing, innovation and technology development.

A stronger biotechnology manufacturing ecosystem can provide several benefits:

Reduced dependence on imported pharmaceutical and biological products.

Improved availability of vaccines and essential medicines.

Development of indigenous research and manufacturing technologies.

Increased investment in biotechnology start-ups.

Expansion of pharmaceutical and biotechnology exports.

Generation of specialised employment opportunities.

Improved preparedness for future public health emergencies.

However, these benefits require consistent regulatory implementation, research funding, skilled professionals and reliable manufacturing infrastructure.

Recommendations for effective legal governance

An effective legal framework for Atmanirbhar Bharat and biotechnology manufacturing should include:

Strong intellectual property protection for qualifying domestic biotechnology inventions.

Simplified and transparent regulatory approval procedures.

Increased investment in indigenous research and development.

Strong biosafety and environmental compliance mechanisms.

Incentives for domestic production of critical biological materials.

Improved collaboration between universities and biotechnology companies.

Affordable access to essential vaccines and biological medicines.

Effective technology transfer and licensing arrangements.

International quality certification and manufacturing standards.

Strong protection of biological resources and benefit-sharing rights.

Conclusion

Atmanirbhar Bharat represents an important opportunity to strengthen India's biotechnology manufacturing capabilities and reduce dependence on foreign technologies and essential biological products. Through domestic innovation, research investment, industrial development and technology transfer, India can strengthen its position in the global biotechnology sector.

The legal framework supporting this objective includes the Patents Act, 1970, Drugs and Cosmetics Act, 1940, New Drugs and Clinical Trials Rules, 2019, Environment (Protection) Act, 1986 and Biological Diversity Act, 2002.

Judicial decisions such as Novartis AG v. Union of India, Bayer Corporation v. Union of India, Dimminaco A.G. v. Controller of Patents and Designs and Vellore Citizens' Welfare Forum v. Union of India establish important principles concerning intellectual property, pharmaceutical manufacturing, technology development and environmental responsibility.

Ultimately, successful biotechnology manufacturing under Atmanirbhar Bharat requires a balanced legal approach that promotes indigenous innovation, protects public health, encourages responsible investment and ensures environmental sustainability.